Anoxic brain injury — from cardiac arrest, near-drowning, respiratory failure or other causes — causes immediate neuronal death and triggers a prolonged secondary injury cascade. HBOT delivers concentrated oxygen to ischemic brain tissue, reduces cerebral edema, restores mitochondrial function and activates the neuroplasticity pathways needed for functional recovery.

Actinomycosis is caused by anaerobic Actinomyces bacteria that thrive in low-oxygen tissue environments. HBOT directly kills these organisms by flooding infected tissue with high-pressure oxygen, potentiates the antibiotics essential for treatment, and resolves the chronic draining sinuses and fibrotic masses that standard antibiotic courses alone often cannot fully clear.

Research shows rheumatoid arthritis patients who receive HBOT make remarkable recoveries, with dramatic decreases in inflammation and surprising relief from joint pain.

No current therapy slows the underlying neurodegeneration of Alzheimer's disease. HBOT targets the cerebral hypoperfusion, neuroinflammation and mitochondrial dysfunction driving the disease — with emerging clinical evidence of meaningful improvements in cognitive function and quality of life following treatment.

Research shows HBOT increases telomere length and clears senescent cells — effectively reversing age-related decline. Patients think faster, feel greater vitality and experience less pain.

Over 26 years of treating children with Autism Spectrum Disorder, we have consistently seen meaningful improvements in cognition, language, motor skills and social interaction.

HBOT is the primary medical treatment for resolving decompression sickness and air or gas embolisms. A retrospective review of 656 cases showed 78% full recovery rate with HBOT.

Cluster headaches cause some of the most severe pain in human experience — attacks of searing, one-sided orbital pain occurring up to 8 times daily during cluster periods. HBOT is proven in randomized controlled trials to abort acute cluster headache attacks within 15–30 minutes, providing rapid, effective relief without cardiovascular risk — making it a valuable option when triptans are contraindicated or inadequate.

CRPS produces burning pain, allodynia and progressive disability driven by neuroinflammation, oxidative stress and sympathetic nervous system dysregulation that standard pain treatments rarely adequately control. HBOT targets these root mechanisms — suppressing neuroinflammation, restoring tissue oxygenation and reducing oxidative stress in the affected limb — with randomized trial evidence supporting significant pain reduction and improved function.

Cyanide poisons the body’s cells by blocking the enzyme that uses oxygen to make energy — causing cellular suffocation even when blood oxygen is normal. HBOT is a Medicare-approved treatment that floods tissues with high-pressure dissolved oxygen, directly outcompeting cyanide for cytochrome c oxidase and restoring cellular energy production throughout the body.

HBOT reoxygenates suffocating ischemic tissue, reduces dangerous compartment pressure, stimulates new blood vessel growth and can save limbs and lives in compartment syndrome.

Studies show that between 78% and 88% of Crohn's patients who receive hyperbaric oxygen therapy experience significant improvement in symptoms and disease activity.

HBOT restores oxygen to crushed tissue, reduces compartment swelling, promotes blood vessel growth and saves limbs that would otherwise require amputation. Medicare approved.

Central retinal artery occlusion causes sudden vision loss that can be permanent. HBOT delivers oxygen directly to the retina, bypassing the blocked artery. Treatment within 24 hours is critical.

ME/CFS involves reduced blood flow to the brain, neuroinflammation and impaired cellular energy production. HBOT addresses all three mechanisms — delivering oxygen to hypoperfused brain regions and reducing the neuroinflammation and mitochondrial dysfunction that drive profound fatigue.

CP brain injuries leave dormant neurons that are alive but not functioning due to chronic oxygen deprivation. HBOT restores oxygen to these neurons and activates the neuroplasticity mechanisms that support recovery.

Clinical studies show HBOT reduces central sensitization and outperforms standard pain medications for conditions like fibromyalgia, offering safe, drug-free pain management.

Brain imaging studies confirm HBOT stimulates neuroplasticity, angiogenesis and stem cell regeneration in TBI patients, with measurable cognitive and functional improvements.

HBOT is the definitive treatment for carbon monoxide poisoning, removing carboxyhemoglobin from the bloodstream faster than any other therapy and preventing delayed neurological damage.

Researchers have found that HBOT creates neuroplasticity — the brain can regenerate. Our dementia patients have seen significant improvements in memory, cognition and overall brain function.

Decompression sickness occurs when dissolved gases form bubbles in the blood and tissues after a diver ascends too quickly. HBOT is the only definitive treatment — recompressing the body under pressure to dissolve those bubbles and eliminate them safely.

Studies show HBOT decreases the need for amputations by over 50%. Our clinic achieves over 90% wound healing success rate for diabetic patients. Medicare approved.

Many depression patients have underlying brain injuries from concussions, accidents or surgery. HBOT oxygenates damaged brain tissue, reactivates idling neurons and resolves the physical disorders driving depression.

When blood loss is so severe that transfusion cannot restore adequate oxygen delivery — or when transfusion is refused or unavailable — HBOT can sustain vital organ oxygenation by flooding plasma with dissolved oxygen that bypasses the red blood cell system entirely.

Research shows HBOT virtually eliminates physiological causes of ED in over 80% of patients by increasing penile blood flow, reducing fibrosis and promoting new blood vessel growth.

Our physician partners have referred hundreds of patients with failing grafts and flaps, achieving a higher than 90% salvage success rate with HBOT. Medicare and insurance covered.

Brain imaging studies show HBOT heals the lesions found in fibromyalgia patients, with 70% showing dramatic symptom improvement and many no longer meeting FMS diagnostic criteria.

HBOT creates an oxygen-rich environment directly toxic to the anaerobic bacteria that cause gas gangrene — neutralizing toxins, restoring tissue oxygenation and helping preserve tissue that would otherwise be lost.

Interstitial cystitis causes chronic bladder pain, urgency and frequency that can be severely debilitating — and that frequently fails to respond adequately to conventional treatments. HBOT reduces bladder wall inflammation, promotes regeneration of the damaged urothelial barrier, and has demonstrated significant improvements on validated IC symptom measures in randomized controlled trials.

Brain abscesses create profoundly hypoxic environments where antibiotics lose effectiveness and anaerobic bacteria thrive. HBOT restores tissue oxygen to this environment, killing the bacteria, restoring immune function and reducing the brain swelling that threatens survival.

Long COVID leaves patients with brain fog, crushing fatigue, post-exertional malaise and cognitive impairment — symptoms that persist for months or years after COVID infection. HBOT targets the neuroinflammation, impaired brain perfusion and mitochondrial dysfunction at their root, with a 2022 randomized trial demonstrating objective neurological improvement.

HBOT eradicates the spirochetes responsible for Lyme disease, reduces inflammation, kills bacteria and heals the neurological and systemic damage they cause. 70% of patients achieve complete recovery.

MRONJ develops when bisphosphonates or denosumab suppress the bone remodeling and angiogenesis that maintain jaw bone health — leaving patients with exposed, necrotic jaw bone that cannot heal. HBOT stimulates new blood vessel formation in avascular jaw bone, restores osteoblast function, controls anaerobic infection and significantly improves outcomes when combined with surgical management.

AMD progressively destroys the macula in an increasingly hypoxic, oxidatively stressed retinal environment. HBOT delivers concentrated oxygen to oxygen-deprived macular tissue, reduces the oxidative damage driving RPE degeneration, and has demonstrated measurable visual improvements in clinical trials.

HBOT improves oxygenation in demyelinated nervous tissue, reduces the neuroinflammation driving MS lesion formation, and consistently reduces the fatigue that affects up to 90% of MS patients.

Clinical experience shows HBOT often resolves active migraines within a single treatment, while a full protocol can dramatically reduce migraine frequency for a year or more.

NSTIs are surgical emergencies. HBOT, used alongside aggressive debridement and antibiotics, directly kills the anaerobic bacteria responsible, reduces the toxemia driving rapid deterioration and helps preserve tissue that surgery alone would lose.

Over 25 years, Bay Area Hyperbarics has healed thousands of patients with stubborn non-healing wounds by regrowing healthy tissue, killing infections and mobilizing stem cells.

HBOT increases the cure rate for chronic refractory osteomyelitis from 50% with surgery and antibiotics alone to 86% when used as an adjunct treatment. FDA and Medicare approved.

Pressure ulcers develop when sustained pressure starves tissue of oxygen, creating wounds that resist healing because the same ischemia that caused the ulcer prevents it from closing. HBOT restores oxygen to the wound bed, stimulates angiogenesis in devascularized tissue, reconstitutes immune killing in infected wounds, and accelerates closure — with Medicare coverage available for qualifying Stage 3 and Stage 4 wounds.

Peripheral neuropathy causes pain, burning, tingling and loss of sensation in the hands and feet — most commonly from diabetic damage to the tiny blood vessels supplying peripheral nerves. HBOT restores oxygen to these ischemic nerve fibers, reduces the neuroinflammation driving progressive nerve loss, and has demonstrated measurable improvements in nerve fiber density, pain scores and sensory function in clinical studies.

PAD blocks the arteries supplying the legs, depriving muscle and skin of the oxygen they need to function and heal. HBOT restores tissue oxygenation, stimulates new blood vessel growth and reduces the inflammation that impairs PAD wound healing — preserving limbs and improving quality of life.

PTSD leaves measurable damage in the brain — reduced blood flow in the prefrontal cortex and hippocampus, chronic neuroinflammation, and disrupted circuits for emotional regulation and memory. HBOT directly addresses these neurobiological mechanisms, with controlled trials demonstrating meaningful reductions in PTSD symptoms, anxiety, hyperarousal and sleep disturbance.

HBOT improves cerebral oxygenation, reduces the neuroinflammation driving dopamine neuron loss, and activates neuroprotective gene expression — offering Parkinson's patients a meaningful adjunctive therapy.

HBOT helps surgical incisions heal faster, reduces infection risk, minimizes scarring and gets patients back to normal activities sooner by delivering concentrated oxygen to healing tissue.

Studies show 76% of patients with radiation-induced hemorrhagic cystitis experience complete or partial resolution after HBOT. Hemorrhagic cystitis — blood in the urine, bladder pain and urgent urination caused by radiation damage — is a Medicare-approved HBOT indication.

Research shows HBOT heals radiation proctitis in up to 89% of patients by regrowing blood vessels, reducing inflammation and regenerating damaged rectal tissue. FDA approved and Medicare covered.

RP progressively destroys photoreceptors in an increasingly hypoxic outer retina. HBOT restores the oxygen gradient that remaining photoreceptors depend on, slowing degeneration and improving vision in a condition that currently has no other proven disease-modifying treatment.

Radiation therapy saves lives, but it can permanently destroy the blood vessels that keep bone and soft tissue alive. HBOT reverses this damage by stimulating new blood vessel growth in radiation-injured tissue.

HBOT reverses radiation-induced enteritis, proctitis, cystitis, fibrosis and vascular injury in the abdomen and pelvis. Over 50% of patients show significant clinical benefit.

HBOT stops ongoing radiation damage to breast tissue, bones, skin and nerves. It stimulates angiogenesis, corrects ischemia after mastectomy and reduces pain and fibrosis.

HBOT saves loosened teeth, regrows healthy bone and gums, heals mouth sores and softens fibrous tissue in patients with osteoradionecrosis. FDA and Medicare approved.

Scleroderma’s microvascular destruction progressively deprives the skin and extremities of the oxygen they need to survive and heal — producing painful digital ulcers, severe Raynaud’s attacks and non-healing wounds. HBOT restores oxygen to ischemic tissue, stimulates new blood vessel growth and has demonstrated meaningful improvements in digital ulcer healing and Raynaud’s severity in clinical studies.

Most neurological damage in SCI accumulates not from the initial impact but from the secondary injury cascade — hours of ischemia, edema and inflammation that can be interrupted with early HBOT. In chronic SCI, HBOT supports neurological function, pressure ulcer healing and quality of life alongside rehabilitation.

Clinical studies confirm HBOT induces neuroplasticity in chronic neurological deficiencies after stroke, with up to 55% of patients experiencing significant functional improvement.

Professional, Olympic and recreational athletes use HBOT to accelerate recovery from injuries and surgery. HBOT reduces swelling by 30% and speeds healing by 50% or more.

According to the National Institute on Deafness, most people with sudden hearing loss recover within two weeks if they receive hyperbaric treatment. Time is critical — early treatment produces the best outcomes.

HBOT delivers concentrated oxygen to oxygen-starved burn tissue, reducing edema, combating infection, and stimulating the new blood vessel growth and collagen formation that burns need to heal.

HBOT is effective for tinnitus that accompanies acute cochlear injury — from sudden sensorineural hearing loss, acoustic trauma or barotrauma — when treatment begins within the first few weeks of onset. It is not effective for long-standing chronic tinnitus or tinnitus without a cochlear ischemic component. We are transparent about this distinction so patients can make an informed decision.

HBOT is a game-changer for acute UC flares, achieving high remission rates, reducing hospital visits and colectomy risk, and decreasing harmful inflammation safely and effectively.

Venous stasis ulcers develop when chronic venous hypertension progressively starves lower leg tissue of oxygen, creating wounds that resist standard wound care. HBOT restores tissue oxygen to the ischemic wound bed, stimulates angiogenesis and reconstitutes the immune and fibroblast function needed to close wounds that compression and dressings alone cannot heal.